2 results match your criteria neutrophils' platelets'

  • Page 1 of 1

COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study.

PLoS One 2020 28;15(12):e0244129. Epub 2020 Dec 28.

National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.

Background: Detailed temporal analyses of complete (full) blood count (CBC) parameters, their evolution and relationship to patient age, gender, co-morbidities and management outcomes in survivors and non-survivors with COVID-19 disease, could identify prognostic clinical biomarkers.

Methods: From 29 January 2020 until 28 March 2020, we performed a longitudinal cohort study of COVID-19 inpatients at the Italian National Institute for Infectious Diseases, Rome, Italy. 9 CBC parameters were studied as continuous variables [neutrophils, lymphocytes, monocytes, platelets, mean platelet volume, red blood cell count, haemoglobin concentration, mean red blood cell volume and red blood cell distribution width (RDW %)]. Read More

View Article and Full-Text PDF
January 2021

Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients.

Eur J Haematol 2020 Feb 12;104(2):138-144. Epub 2019 Dec 12.

Cellular Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.

Objectives: ASCT is currently the "gold standard" first-line treatment for multiple myeloma patients younger than 65 years old, and limited data on efficacy and safety in older patients are available.

Methods: We retrospectively analyzed a cohort of 83 newly diagnosed multiple myeloma patients aged 65 or older. All patients were evaluated for fitness at diagnosis and after bortezomib-based induction treatment. Read More

View Article and Full-Text PDF
February 2020
  • Page 1 of 1